A. Tasciotti

发表

Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine.

P. van Damme, G. Leroux-Roels, I. De Ryck, 2019, Vaccine.

Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study

G. Di Maro, M. Janssens, T. Schwarz, 2022, Respiratory Research.

Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.

P. Castiglia, M. de Martino, G. Bona, 2016, Vaccine.

The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer

R. Berardi, S. Cascinu, P. Conte, 2015, Cell adhesion & migration.

Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.

C. Brightling, W. MacNee, J. Hedner, 2019, Vaccine.

Isolated limb perfusion with the tumor‐targeting human monoclonal antibody–cytokine fusion protein L19‐TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma

L. Zardi, D. Neri, A. Maurichi, 2013, Journal of surgical oncology.

Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours

R. Berardi, D. Neri, F. Braud, 2013, Journal of Cancer Research and Clinical Oncology.

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

F. D. De Braud, C. Garbe, D. Neri, 2011, Clinical Cancer Research.

Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.

E. Kerwin, H. Watz, F. Maltais, 2022, The Lancet. Respiratory medicine.

Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial

G. Leroux-Roels, G. Di Maro, D. Casula, 2021, Vaccine: X.

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

F. D. De Braud, C. Garbe, D. Neri, 2011, Clinical Cancer Research.

Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials.

S. Cascinu, P. Conte, D. Neri, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

V. Anttila, A. Borobia, O. Launay, 2023, Human vaccines & immunotherapeutics.